Consolidated loss masks strategy; margin recovery timing key

Revenue +12.8% YoY supports growth narrative, but consolidated loss -₹7.9Cr contradicts 'softer but strong' framing

Acknowledged Toamasina port shut ~30 days Mar-Apr; clove cost inflation and RM delays impacted margins (16.7% vs prior baseline)

Stated but unverified; no order sizes disclosed despite analyst pressure; initial orders secured but scale timing Q3-Q4

EBITDA margin 3.3% vs prior FY28 target 16-18%; depreciation burden ₹9.1Cr structural until revenue ramps significantly

Currently ~1-2% (only initial orders Q1); ramp requires Q3-Q4 success across three new verticals simultaneously; high execution risk

Prior call expected FY27 'significantly better than FY26'; now management says 'ramp-up year only, no guidance' as new products remain in approval phase

₹265/270Cr (~98%) capitalized; depreciation hit full P&L this quarter (₹9.1Cr); no further major capex expected, but now must drive revenue

Port reopened by May, but clove costs remain elevated; gross margin 16.7% implies higher raw material pricing carries forward into FY27

Two of world's largest companies in category approved; new competitive validation; orders expected Q3-Q4 but size undisclosed

Western Hemisphere (US, Latin America) demand ramping; mint harvest May-June will lift Q2-Q3 exports; core business demand back to normal levels

Cooling agents Q3 FY27 after customer audits; Safranal Q2-Q3 FY27 after approvals; phenol Q3 trial, Q4 commercial with meaningful revenue Q4 FY27

Timing mismatch: depreciation/interest kicked in but Krystal revenue not yet. As new products ramp, profitability will follow. Working capital for Krystal lower than Gem business.

Trees not uprooted; regrow leaves in 2-3 years. Diversified sourcing across East Africa. Port delays resolved; material now flowing. No structural tightness expected.

Should be fairly close to those numbers by Q3-Q4; shipping delays to Western Hemisphere are main constraint; orders expected as supply normalizes

Not disclosing order values or customer names as of now; will give clarity as quarters pass. Large pipeline of specialty products in various approval stages.

Shipping challenges + Madagascar delays + May-June mint harvest seasonality meant exports happened but not yet recognized (in transit). Rollover happening in Jul-Aug.

Dahej capex complete; Krystal expected >50% of revenue by FY28; timing dependent on Q3-Q4 FY27 new product ramp success

Safranal Q2+, cooling agents Q3+, phenol Q3+; staggered timing creates quarter-by-quarter visibility gap; management avoiding quantification

Requires operating leverage as utilization scales; currently 3.3% EBITDA margin in Q1 FY27 suggests significant ramp needed; target assumes new product mix >50% with higher margins

Current 3.3% EBITDA margin structurally weak due to depreciation (₹9.1Cr) and standby capacity costs; recovery timing tied to new product ramp, not provided

No major capex expected; focus now on revenue ramp and utilization improvement; depreciation will remain structural headwind until volumes scale

Safranal, cooling agents, phenol all ramping simultaneously post-approval; any single vertical underperforming delays overall margin recovery; FY28 guidance assumes successful multi-product launch

₹9.1Cr depreciation (Q1) converts standalone profit ₹7.3Cr into consolidated loss -₹7.9Cr; depreciation structural until Krystal revenue >50% of total and utilization improves significantly; extends loss period if ramp delays

Madagascar cyclone (Mar-Apr) shut Toamasina port ~30 days, caused RM delays and cost inflation; clove tree uprooting (10-year+ recovery if severe) poses structural risk; though trees intact this time, vulnerability persists

Cooling agents orders from two of world's largest companies; Safranal orders from multiple MNCs; but order sizes, contract durations, and customer concentration not disclosed. Loss of one major customer could derail Q3-Q4 ramp; small initial orders could underscore guidance miss

Each new vertical has approval, stability testing, and supply ramp phases that can slip; if Q3-Q4 FY27 contributions fall short (e.g., delays in phenol trial, cooling agents stability testing extension), FY27 will remain loss-making and push FY28 targets at risk